Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 12-Month Low – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price reached a new 52-week low on Monday . The company traded as low as $5.19 and last traded at $5.34, with a volume of 4151746 shares changing hands. The stock had previously closed at $5.81.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Trading Down 9.2 %

The company has a market capitalization of $2.12 billion, a P/E ratio of -3.46 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average price is $7.44 and its 200 day moving average price is $7.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same period last year, the company earned ($0.42) earnings per share. The business’s revenue for the quarter was down 57.8% compared to the same quarter last year. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Softbank Group CORP. bought a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $99,152,000. Novo Holdings A S bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Vanguard Group Inc. increased its position in shares of Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after acquiring an additional 9,737,196 shares during the last quarter. State Street Corp lifted its holdings in Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after acquiring an additional 4,120,685 shares during the period. Finally, Norges Bank purchased a new position in Recursion Pharmaceuticals in the fourth quarter worth $23,429,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.